HEALTH CARE

Lidak Shares Up 4.6%: The stock price jump came after La Jolla-based Lidak Pharmaceuticals said it had received Food and Drug Administration approval to begin human tests of a potential skin cancer therapy. Lidak said the trials will involve 18 patients at the UC San Diego Cancer Center. The study will last about a year. Lidak’s multivalent immunogen technology uses the patient’s own immune system to fight the invading tumor. Lidak said the trials will be used primarily to investigate the safety of the technology with patients in the late stages of the disease. Lidak shares closed at $4.25, up 19 cents on the Nasdaq.